As a control, we randomly selected 12 cancer type–matched cell lines without simultaneous mutations in KRAS and SMAD4 (hereafter referred to as Control cell lines) for which published in vitro radiosensitivity data were available (Table 2). This evidence concerns the gene SMAD4 and cancer.